Table 4.

Univariate analysis of the economic impact of ESBL and non-ESBL-producing K. pneumoniae in Euros.

	Non-ESBL med[P25,P75]	ESBL med[P25,P75]	p-Value *
Cost of hospitalization	3688 [1783,4141]	6718 [3322,9611]	<0.001
Cost of pharmacy	457 [174,577]	888 [325,1158]	0.001
Cost of antibiotics	47 [7,31]	380 [87,544]	<0.001
Cost of nursery	1809 [880,2294]	4581 [2375,6630]	<0.001
Cost of laboratory	165 [39,201]	171 [81,192]	0.852
Cost of radiology	94 [0,111]	62 [1,72]	0.205
Cost of inter consultations	60 [0,33]	65 [0,71]	0.818
Cost of Emergency Room visits	341 [0,760]	463 [0,663]	0.218

* Student’s t-test or Mann–Whitney U. ESBL: extended spectrum betalactamases; med: median; P₂₅:1st quartile; P₇₅:3rd quartile